Johnson & Johnson CEO: America’s innovation advantage starts with health |
Johnson & Johnson CEO: America’s innovation advantage starts with health
Over the past century, American innovation has transformed healthcare, turning once-unimaginable ideas into lifesaving realities for patients around the world.
As the United States approaches its 250th anniversary, that legacy is not slowing down.
After decades working at the intersection of science, manufacturing, and patient care, I see every day that America’s capacity for innovation is not fading. It is gaining momentum.
What sets the United States apart is not invention alone. It is our ability to translate discovery into real-world impact. Today the United States leads the world in biopharmaceutical innovation, with American companies driving 55% of global R&D and producing more new medicines than any other country. That leadership translates directly to patients, with roughly 70% of new medicines launching first in the U.S., giving Americans access to breakthrough treatments months, often years, ahead of other countries.
We are entering an era where breakthroughs move faster from lab to patient. Diseases are detected earlier. Treatments are tailored more precisely. High-quality care is reaching more people. Progress is no longer defined only by what we discover, but by how early and effectively we put those discoveries to........